Medicine
Cycloset 0.8 mg tablet
Cycloset 0.8 mg tablet is a prescription medicine containing Bromocriptine for oral use, marketed by Avvisto Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store and dispense: At 20-25°C (68-77°F) in a tight, light-resistant…
Key facts
- Active ingredient (INN)
- Bromocriptine
- Brand
- Cycloset
- Strength
- 0.8 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 21 tablets, 200 tablets
- Marketing authorisation holder
- Avvisto Therapeutics
- Manufacturer
- Avvisto Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store and dispense: At 20-25°C (68-77°F) in a tight, light-resistant container. See USP Controlled Room Temperature.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G02CB01 Bromocriptine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 May 2024
- Identifiers
- RxCUI 859077, 859081DailyMed set ID e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20NDC 73515-123Application NDA020866
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 21 tablet in 1 bottle | 73515-123-21 | Avvisto Therapeutics | 23 May 2024 |
| 200 tablet in 1 bottle | 73515-123-30 | Avvisto Therapeutics | 23 May 2024 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 28 June 1978 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bromocriptine
Clinical summary
Bromocriptine is an ergot derivative indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults, among other approved uses. It is available as tablets and capsules for oral use. MedsAcross supplies Bromocriptine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BromocriptineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Bromocriptine Mesylate prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Cycloset 0.8 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.